Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lonza To Boost Cytotoxic Capacity

by Rick Mullin
May 16, 2011 | A version of this story appeared in Volume 89, Issue 20

Lonza will invest $27 million to expand cytotoxic manufacturing capabilities at its fine chemicals plant in Visp, Switzerland. The expansion will add multikilogram-scale production of cytotoxic active pharmaceutical ingredients to a high-potency facility that now manufactures APIs to current Good Manufacturing Practice standards on a gram scale. Stefan Stoffel, head of Lonza’s chemical manufacturing business unit, says the project will establish integrated manufacturing and development capabilities spanning technologies including highly active APIs, cytotoxics, peptides, and antibody-drug conjugates. Cytotoxic APIs, typically used in oncology drugs, are among the fastest-growing segments in drug chemical ingredients, according to Lonza.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.